Clinical Trial

This is a Multi-centre, Multi-drug, Platform Study in Chinese Participants Living With Obesity / Overweight

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated July 2, 2026 (before its estimated August 6, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study is to assess the safety and tolerability, PK characterisation, efficacy, and immunogenicity of the study intervention, and it allows assessment of the monotherapy or combination therapy of AZD6234 and AZD9550 in different sub-studies.
Protocol Amendment History 2 changes
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-07-03
notable Enrollment reduced: 871 -> 14 participants 2026-07-03
Trial Details
NCT Number NCT07017179
Lead Sponsor AstraZeneca
Conditions Obesity/Overweight
Enrollment 14 participants
Start Date 2025-05-20
Primary Completion 2026-08-06 (estimated)
Study Completion 2026-08-06 (estimated)
Updated on ClinicalTrials.gov 2026-07-02